A case report and literature review of chronic graft-versus-host disease manifesting as polymyositis

International Journal of Hematology
Fotios V MichelisJeffrey H Lipton

Abstract

Polymyositis (PM) is a rare but documented manifestation of chronic graft-versus-host disease (cGvHD) post allogeneic hematopoietic cell transplantation (HCT). We present the case of a 70-year-old male patient who developed severe cGvHD-related PM 3 years after undergoing allogeneic HCT for acute myeloid leukemia. The patient responded to steroids and was maintained long-term with hydroxychloroquine as a steroid-sparing agent. We review the literature concerning the diagnosis and treatment of PM as cGvHD as well as the differentiation of this manifestation from other forms of PM.

References

Aug 1, 1986·Neurology·A Urbano-MárquezC Rozman
Oct 16, 2002·Bone Marrow Transplantation·D R CourielR Champlin
Jan 2, 2003·Rheumatology·A M StevensJ L Nelson
Apr 30, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stephanie J LeeMary E D Flowers
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra H FilipovichMary E D Flowers
Sep 3, 2008·Bone Marrow Transplantation·K OdaUNKNOWN Kanto Study Group for Cell Therapy (KSGCT)
May 28, 2009·International Journal of Hematology·Jae-Sook AhnHyeoung-Joon Kim
Aug 12, 2009·Muscle & Nerve·Jeffrey A AllenAnthony A Amato
Jan 14, 2010·Clinical Rheumatology·Helene Maillard-LefebvrePierre-Yves Hatron
Aug 6, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel WolffErnst Holler
Aug 21, 2012·International Journal of Hematology·Juan MontoroCarlos Solano

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.